Is Ngenla approved for treating Growth Hormone Deficiency in children aged 3 years and older?
Ngenla is a long-acting growth hormone medication designed to treat growth failure caused by the body not making enough growth hormone. It is approved for use in pediatric patients starting at age 3. This approval allows for once-weekly injections instead of daily shots, which can help with treatment adherence for both children and their caregivers.
What the research says
Ngenla is specifically indicated for pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone 2. This long-acting formulation represents a clinically effective alternative to daily recombinant human growth hormone, enabling extended dosing intervals 1. The medication is a human growth hormone analog that addresses the burden of daily injections, which often leads to high rates of non-adherence 5.
What to ask your doctor
- Is my child eligible for Ngenla based on their specific type of growth hormone deficiency?
- How does the once-weekly schedule of Ngenla compare to daily injections for our family's routine?
- What are the potential side effects of Ngenla that I should monitor for in my child?
- Are there any specific testing requirements before starting Ngenla therapy?
This question is drawn from common patient questions about Diabetes & Endocrinology and answered using cited medical research. We do not provide individualized advice.